Phase 2a, open-label, multi-center study of GI-101A or GI-102 (CD80-IgG4 FC-IL2v) in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION)

Start Date31 Jul 2024

Sponsor / Collaborator

Asan Medical Center

NCT05824975 / RecruitingPhase 1/2

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors.

Start Date30 May 2023

Sponsor / Collaborator

GI Innovation, Inc.

100 Clinical Results associated with IL-2Rβ x IL-2Rγ x CD80

100 Translational Medicine associated with IL-2Rβ x IL-2Rγ x CD80

0 Patents (Medical) associated with IL-2Rβ x IL-2Rγ x CD80

Literatures (Medical) associated with IL-2Rβ x IL-2Rγ x CD80

01 Feb 2007·Scandinavian Journal of ImmunologyQ4 · MEDICINE

CD25‐expressing B‐lymphocytes in Rheumatic Diseases

Q4 · MEDICINE

Article

Author: K Strömberg ; M Brisslert ; A Tarkowski ; M Bokarewa ; S Amu

AbstractB cells play an important role in the development of autoimmune diseases due to their production of autoantibodies, antigen‐presenting capacity and production of pro‐inflammatory cytokines. The purpose of the present study was to analyse B cells from rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients, with respect to their expression of the IL‐2 receptor (IL‐2R) subunit CD25. Using flow cytometry, we found that CD25+ B cells from RA patients expressed significantly higher frequencies of CD122 and CD132 than CD25+ B cells from control subjects, indicating a fully functional IL‐2R. These CD25+ B cells also expressed higher frequencies of the co‐stimulatory molecule CD80, whereas IgM and IgA expression was decreased compared with CD25+ B cells from healthy controls. In addition B cells from SLE patients co‐expressed CD25 together with CD80, CD122, and CD132, but to a lower degree IgD and IgM, when compared with healthy controls. Taken together, our results indicate that CD25+ B cells from RA and SLE patients are in a highly activated state, display a more mature phenotype and suggest that this B cell subset may be involved in the pathogenesis of RA and SLE.

01 Nov 2006·Scandinavian Journal of ImmunologyQ4 · MEDICINE

B‐cell CD25 Expression in Murine Primary and Secondary Lymphoid Tissue

Q4 · MEDICINE

Article

Author: Brisslert, M. ; Gjertsson, I. ; Amu, S. ; Tarkowski, A.

AbstractB cells are in analogy with T cells capable of expressing functional IL‐2 receptors. IL‐2R α‐chain (CD25) positive T cells have been studied in detail but not much is known about CD25 positive B cells. The aim of this study was to examine the phenotypic properties of the CD25 expressing B cells collected from different lymphoid organs in mice. Samples were stained for various cell surface markers and analysed using flow cytometry. We found that approximately 49% of B cells in bone marrow, 16% in peritoneal cavity, 2% in spleen and 1% in lymph nodes express CD25. In contrast, CD25 expressing B cells were not found in the blood or in Peyer's patches. Phenotypic characterization showed that CD25+ B cells in spleen, lymph nodes and peritoneal cavity have higher expression of AA4.1, CD5, CD69, CD80, CD86, CD122, CD132, IgA, IgG and IgM on their surface in comparison with CD25− B cells. In contrast, expression of IgD and IA‐IE was lower on CD25+ B cells in spleen and lymph nodes. In bone marrow, the expression of CD5, CD80, CD86, CD122, CD132, IgA, IgD and IgM was lower, while the expression of AA4.1, IgG and IA‐IE was increased on CD25+ B cells compared with CD25− B cells. In conclusion, our results indicate that B cells expressing CD25 are phenotypically distinctly different from those that are CD25 negative. Our findings suggest that CD25+ B cells are more prone to efficient antigen presentation and display a more mature phenotype.

01 Apr 2006·ImmunologyQ3 · MEDICINE

Phenotypic and functional characterization of human CD25⁺ B cells

Q3 · MEDICINE

Article

Author: Kajsa Wing ; Andrej Tarkowski ; Mikael Brisslert ; L. Vincent Collins ; Pia Larsson ; Maria Bokarewa

SummaryWe demonstrate that humans have a phenotypically and functionally distinct subset of B lymphocytes that express the interleukin (IL)‐2 receptor (IL‐2R) α‐chain, cluster of differentiation (CD) 25. We found that one‐third of the circulating CD20+ B cells expressed CD25 and, using fluorescence‐activated cell sorter (FACS) analysis, that these cells were significantly larger and more granulated than B cells not expressing CD25. The simultaneous expression of the other two subunits (CD122 and CD132) and the proliferative responses of cells expressing CD25 to IL‐2 suggested that, in addition to CD25, functional IL‐2 receptors were expressed on this cell population. CD25 expression on B cells was selectively up‐regulated by Toll‐like receptor 2 (TLR2), TLR4, and TLR9 ligands but not by a TLR3 ligand or Epstein–Barr virus (EBV) stimulation. Blockade of the nuclear factor (NF)‐κB pathway completely abolished CD25 up‐regulation by these B cells. Interestingly, CD25+ B cells expressed significantly higher levels of surface immunoglobulins but lacked the ability to secrete immunoglobulin (Ig), as compared with CD25− B cells. Furthermore, CD25+ B cells performed significantly better as antigen‐presenting cells in allogeneic mixed lymphocyte reactions (MLR), which may be a result of their expression of high levels of the costimulatory molecules CD27 and CD80. Finally, blocking of CD25 on B cells led to an almost total abrogation of MLR. Our results indicate that CD25+ B cells have distinct phenotypic and functional properties, including the ability to contribute to antigen presentation, which is linked to their expression of CD25. Finally, the differential regulation of CD25 expression via selective TLR ligands suggests a role for CD25+ B cells in bridging innate and acquired immune responses.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis